Accessibility Menu
Telesis Bio logo

Telesis Bio(OTC) DNAY

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-92%
1 Month-9%
N/A
Telesis Bio last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-31
Telesis Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-19
1 month-9.09%USD 0.002026-07-23
3 month-98.11%USD 0.052026-05-29
Year to date-98%USD 0.052025-12-31
1 year-91.67%USD 0.012025-08-29
3 year-100%USD 23.222023-09-01
5 year-100%USD 248.222021-09-01
Since inception-100%USD 333.002021-06-18

Telesis Bio Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$17.33M

Net Income (TTM)

-$40.08M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

DNAY News

3 strands of DNA

Why Codex DNA Trounced the Market Today

Eric VolkmanDec 29, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telesis Bio

Codex DNA, Inc. operates in the synthetic biology sector, focusing on the development, manufacturing, and sale of advanced instruments, reagents, and complementary services. The company primarily serves pharmaceutical firms and academic laboratories globally, while also catering to government institutions and contract research organizations.

Products and Services
  • BioXp system for transforming digital DNA sequences into synthetic DNA
  • BioXp portal for online DNA sequence design and assembly
  • Biofoundry Services for endpoint-ready BioXp products
Growth Outlook
  • Recent quarterly revenue of $1.57 million shows consistent demand
  • Strong gross profit margin of 64.43% in Q3 2024 indicates operational efficiency
  • Significant cash reserves of $3.72 million support ongoing R&D initiatives
Financial Highlights
  • Trailing twelve months revenue of $15.56 million reflects growth potential
  • Operating expenses of $6.15 million in Q3 2024 highlight cost management efforts
  • Net income loss of $7.26 million in Q3 2024 shows room for improvement
Codex DNA, Inc. is positioned in a rapidly evolving industry, leveraging innovative technologies to meet the needs of its diverse customer base. The BioXp system and associated services are designed to streamline the synthetic biology workflow, making it easier for researchers to access and utilize synthetic DNA. The company's focus on R&D and operational efficiency is evident in its recent financial performance, with a notable gross profit margin that suggests effective cost management. Despite facing challenges reflected in net income losses, the substantial cash reserves provide a buffer for continued investment in growth initiatives. Overall, Codex DNA, Inc. presents a compelling opportunity for investors interested in the synthetic biology sector.
AI Generated • Aug 30, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

39

CEO

Eric Esser

Website

telesisbio.com

Headquarters

San Diego, CA 92121-2993, US

DNAY Financials

Key Financial Metrics (TTM)

Gross Margin

61.62%

Operating Margin

-169.18%

Net Income Margin

-173.49%

Return on Equity

-125.42%

Return on Capital

-73.11%

Return on Assets

-67.78%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$8.90M

Operating Income

-$35.06M

EBITDA

-$28.57M

Operating Cash Flow

-$36.28M

Capital Expenditure

-$1.79M

Free Cash Flow

-$38.08M

Cash & ST Invst.

$4.51M

Total Debt

$16.29M

Telesis Bio Performance Analysis

Telesis Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 11,043,000N/A
20222022-12-31USD 27,435,000148.4%
20232023-12-31USD 27,509,0000.3%
Telesis Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-3037.0%
Q32023-09-30-35.7%
Q22024-06-30N/A
Q32024-09-301.0%
Telesis Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -23.92N/A
20222022-12-31USD -29.6123.8%
20232023-12-31USD -29.56-0.2%
Telesis Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-3024.3%
Q32023-09-30-32.1%
Q22024-06-30N/A
Q32024-09-3046.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$1.57M

-75.2%

Gross Profit

$1.01M

-71.3%

Gross Margin

64.43%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

212

N/A

Net Income

-$7.26M

+34.7%

EBITDA

$1.01M

+109.2%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$4.51M

-85.9%

Total Debt

$16.29M

-60.9%

Accounts Receivable

$1.26M

-78.4%

Inventory

$1.10M

-52.1%

Long Term Debt

$14.09M

-65.6%

Short Term Debt

$2.21M

+184.9%

Return on Assets

-67.78%

N/A

Return on Invested Capital

-74.79%

N/A

Free Cash Flow

-$4.54M

+70.1%

Operating Cash Flow

-$4.38M

+64.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RADRite Aid Corporation
$0.65-16.81%
ISOIsoPlexis Corporation
$0.76+0.00%
EYENEyenovia, Inc.
$7.56+3.99%
CERCCerecor Inc.
$2.93-1.68%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About DNAY

What is the current price of Telesis Bio?

Telesis Bio is trading at N/A per share.

What is the 52-week range for Telesis Bio?

Over the past 52 weeks, Telesis Bio has traded between N/A and N/A.

How much debt does Telesis Bio have?

As of the most recent reporting period, Telesis Bio reported total debt of $16.29M.

How much cash does Telesis Bio have on hand?

Telesis Bio reported $3.82M in cash and cash equivalents in its most recent financial results.

What is Telesis Bio’s dividend yield?

Telesis Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services